Chen, Wei
Zhang, Ke
Dong, Peiling
Fanning, Gregory
Tao, Chengcheng
Zhang, Haikun
Guo, Shicheng
Wang, Zheng
Hong, Yaqiang
Yang, Xiaobo
Lai, Shujuan
Ding, Huiguo
Zhao, Haitao
Zeng, Changqing
Protzer, Ulrike
Zhang, Dake http://orcid.org/0000-0001-9508-8209
Funding for this research was provided by:
Youth Innovation Promotion Association of the Chinese Academy of Sciences (2016098)
National Natural Science Foundation of China (81201700)
Major State Basic Research Development Program of China (2014CB542006)
Key Research Program of the Chinese Academy of Sciences (KJZD-EW-L14)
Beijing Natural Science Foundation (7192158)
Fundamental Research Funds for the Central Universities (3332018032)
Capital's Funds for Health Improvement and Research (2018-1-1151)
Article History
Received: 9 September 2019
Accepted: 18 January 2020
First Online: 25 February 2020
Compliance with ethical standards
:
: Dr. Dake Zhang has a patent pending for the probe-based HBV DNA capture in plasma as a liquid biopsy to monitor HCC development. The authors declare no other potential conflicts of interests.
: The study was approved by the Institutional Review Board at Beijing institute of Genomics (IRB number: 2016H005). The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committee of You’an Hospital.
: An informed consent was obtained from all patients.
: All authors reviewed and approved the final version of the manuscript.